Search
Diethyltoluamide
go.drugbank.com/drugs/DB11282ApprovedDEET products are largely designed to be applied directly to human skin, where the exact mechanisms of actions in which DEET is capable of repelling insects and causing toxicity to humans is still not … Diethyltoluamide (DEET) is the common active ingredient in many insect repellent products. It is widely used to repel biting pests such as mosquitoes and ticks.
Synonyms: 3-methyl-N,N-diethylbenzamide, N,N-diethyl-m-toluamideInternational brands: m-DelpheneBordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10788ApprovedInvestigationalBordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) is a vaccine that contains inactivated acellular pertussis antigen that is isolated from Bordetella pertussis culture.
Mixtures: Repevax Injektionssuspension in einer Fertigspritze, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGEProducts: PERTAGEN® SUSPENSION FOR INJECTION 0.5 ML/DOSECYT006-AngQb
go.drugbank.com/drugs/DB05739InvestigationalIt is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure … CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension.
Omaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … In patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity is lower.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 SubstratesPimozide
go.drugbank.com/drugs/DB01100ApprovedA diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. … Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: พีไซด์ 4, NOROFREN 2 MG TABLET, 10 ADETPertussis vaccine
go.drugbank.com/drugs/DB15274ApprovedInvestigationalPertussis vaccine is under investigation in clinical trial NCT01698346 (Pertussis (Tdap) Vaccination in Pregnancy).
Mixtures: Boostrix Injektionssuspension in einer Fertigspritze, dTaP Booster Injektionssuspension in einer FertigspritzeProducts: Pertussis Vaccine 4 Protect UnitBordetella pertussis pertactin antigen
go.drugbank.com/drugs/DB10789ApprovedInvestigationalBordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis [A31248].
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Covaxis Injektionssuspension in einer Fertigspritze1D09C3
go.drugbank.com/drugs/DB05121Experimentalclass II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing … 1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody.
Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalIt was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsTrilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalTrilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.
Categories: MATE 2-K Inhibitors, MATE 1 Inhibitors